News Search Results
Sep 18, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
a pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Sep 17, 2025, 11:03 ET Landmark UCSF Study Demonstrates Functional Rescue of SCN2A Loss of Function, Underscoring the Potential of Regel Therapeutics' Targeted EpiEditing Platform.
cell-specific promoters, enabling durable rescue of gene expression with minimal off-target effects. Regel's lead programs focus on severe pediatric CNS disorders, including Dravet Syndrome and SCN2A haploinsufficiency. The company is headquartered in Cambridge, MA. For
More news about: Regel Therapeutics Inc.
Sep 17, 2025, 08:30 ET MapLight Therapeutics Announces Initiation of Phase 2 Trial of Novel M1/M4 Muscarinic Agonist ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
positioned as a potential treatment for ADP based on the favorable safety and tolerability profile observed in healthy elderly volunteers in Phase 1 whose CNS exposures achieved or exceeded levels that we anticipate being clinically relevant," said Erin Foff, M.D., Ph.D., Chief
More news about: MapLight Therapeutics, Inc.
Sep 17, 2025, 03:00 ET ARTHEx Biotech Upsizes Series B Financing Round to $87M to Advance Lead Program ATX-01 in Myotonic Dystrophy Type 1 and Expand Pipeline of Targeted RNA Medicines
miR23b - - Funding to also advance a broader pipeline of targeted RNA medicines across areas of high unmet need in muscular, CNS, cardiac conditions - VALENCIA, Spain,
More news about: ARTHEx Biotech
Sep 16, 2025, 08:00 ET Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model
synergistic and durable anti-inflammatory effects. Highlights from Cohort 1: COYA 303 produced significant systemic and CNS immunomodulatory effects in the LPS model of inflammationCOYA 303 significantly (a) enhanced Treg numbers and suppressive function, (b) reduced
More news about: Coya Therapeutics, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers ernennt John Gellatly zum Senior Advisor
YORK, 16. September 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) gab heute die Ernennung von John Gellatly zum Senior Advisor bekannt. Von London aus wird
More news about: Cohen & Steers, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers Appoints John Gellatly as Senior Advisor
YORK, Sept. 16, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today the appointment of John Gellatly as Senior Advisor. Based in London,
More news about: Cohen & Steers, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers benoemt John Gellatly tot senior adviseur
YORK, 16 september 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) kondigde vandaag de benoeming aan van John Gellatly als senior adviseur. Vanuit Londen zal de heer Gellatly nauw samenwerken
More news about: Cohen & Steers, Inc.
Sep 16, 2025, 05:00 ET Cohen & Steers nomme John Gellatly comme conseiller principal
NEW YORK, 16 septembre 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE : CNS) a annoncé aujourd'hui la nomination de John Gellatly au poste de conseiller principal. Basé à Londres, M. Gellatly travaillera en étroite collaboration
More news about: Cohen & Steers, Inc.
Sep 15, 2025, 16:20 ET Cohen & Steers Announces Chief Financial Officer Transition
YORK, Sept. 15, 2025 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced today that Raja Dakkuri, Executive Vice President and Chief Financial Officer, has provided notice of his decision
More news about: Cohen & Steers, Inc.
Sep 15, 2025, 08:00 ET The Korea Industry Daily: Industrial AI EXPO 2025 Concludes, Marking Milestone in Korea's AI-Driven Industrial Transformation
contributions to industrial digital transformation and AI utilization. Government officials and industry leaders—including executives from HD Hyundai, LG CNS, Microsoft Korea, Dassault Systèmes, HP Korea, Salesforce, and major domestic institutions—attended the opening ceremony, underscoring collective commitment
More news about: THE KOREA INDUSTRY DAILY
Sep 15, 2025, 08:00 ET Johnson & Johnson to showcase industry-leading neuropsychiatry innovations at the 2025 Psych Congress Annual Meeting
SPRAVATO® with certain medicine may cause side effects. Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist
More news about: Johnson & Johnson
Sep 14, 2025, 20:00 ET Corero Network Security Bermitra dengan Nextwave Untuk Perluas Perlindungan DDoS Ke Thailand
Corero Network Security (AIM: CNS) (OTCQX: DDOSF) adalah perusahaan terdepan yang diakui dalam hal perlindungan DDoS dan piawai dalam ketersediaan layanan di waktu nyata yang dapat disesuaikan.
More news about: Corero Network Security
Sep 13, 2025, 11:50 ET INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience
$17 from $33 and stated that ALTO-100's data raises questions around the Company's overall biomarker approach to CNS disorders and psychiatry. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class
More news about: Faruqi & Faruqi, LLP
Sep 13, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Alto Neuroscience, Inc. and Certain Officers - ANRO
pro-neurogenesis/neuroplasticity mechanism of action" and has stated that the Company "believe[s] binds a receptor not targeted by other [central nervous system ("CNS")] therapeutics, which would make it first-in-class if approved." On January 12, 2024, Alto filed a registration
More news about: Pomerantz LLP
Sep 11, 2025, 12:00 ET Zhimeng Biopharma's Investigational Drug Approved to Initiate Phase 2 Epilepsy Clinical Trial in China
small-molecule drug discovery focused on the functional cure of chronic hepatitis B (CHB), as well as novel therapies for CNS disorders, including epilepsy, neuropathic pain (e.g., cancer-related pain), amyotrophic lateral sclerosis (ALS), major depressive disorder (MDD), and
More news about: Shanghai Zhimeng Biopharma, Inc.
Sep 11, 2025, 09:41 ET Gene Solutions Secures Patent(1) for Breakthrough Mitochondrial Therapy Platform Targeting Neurological Diseases
Sept. 11, 2025 /PRNewswire/ -- Gene Solutions, a leader in mitochondrial dysfunction genomics and CNS drug discovery, announces the publication of its platform technology patent. The award covers novel technologies underpinning the company's platform
More news about: Gene Solutions
Sep 11, 2025, 08:46 ET Korea University Study Reveals Hidden Complexity in Recurrent Brain Tumors
2025 /PRNewswire/ --Meningiomas are the most common primary brain tumors, accounting for nearly one-third of all central nervous system (CNS) tumors. While most are benign and manageable, 20–30% progress to high-grade forms that behave aggressively, recur frequently, and resist standard treatments.
More news about: Korea University College of Medicine
Sep 11, 2025, 08:00 ET Kazia Therapeutics Reports Complete Ex Vivo Disruption of Large Circulating Tumor Cell Clusters in Stage IV HER2-Positive Breast Cancer with Paxalisib Monotherapy
standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the
More news about: Kazia Therapeutics Limited
Sep 11, 2025, 07:00 ET Corero Network Security Partners with Nextwave to Expand DDoS Protection into Thailand
Corero Network Security (AIM: CNS) (OTCQX: DDOSF), a recognized leader in DDoS protection and champion of adaptive, real-time service availability, announced a strategic partnership with
More news about: Corero Network Security
Sep 10, 2025, 16:45 ET Cohen & Steers Infrastructure Fund, Inc. Declares Distribution for October 2025
https://www.cohenandsteers.com/Symbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 10, 2025, 16:27 ET Cohen & Steers Infrastructure Fund, Inc. Announces Terms of Transferable Rights Offering
https://www.cohenandsteers.comSymbol: (NYSE: CNS)
More news about: Cohen & Steers, Inc.
Sep 10, 2025, 14:30 ET NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons
draw into actionable, patient-specific insights, accelerating innovation for people living with AD." These results will be presented at the CNS Summit 2025 in Boston, November 2nd – 5th by David
More news about: NeuroSense
Sep 10, 2025, 10:00 ET Health Canada Approves Slenyto® - Extended-Release Melatonin Formulation - as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome
commercially available in 45 countries around the world. Neurim has a strong and innovative product pipeline targeting central nervous system (CNS) disorders. * https://health-products.canada.ca/dpd-bdpp/dispatch-repartition
More news about: Neurim Pharmaceuticals
Sep 10, 2025, 10:00 ET Health Canada Approves Slenyto® - Extended-Release Melatonin Formulation - as a Prescription Drug for Insomnia in Children with Autism Spectrum disorder and Smith Magenis Syndrome
commercially available in 45 countries around the world. Neurim has a strong and innovative product pipeline targeting central nervous system (CNS) disorders. * https://health-products.canada.ca/dpd-bdpp/dispatch-repartition
More news about: Neurim Pharmaceuticals